Non-small-cell lung cancer. (Q51021428)

27 March 2018

review article

1 reference

title

Non-small-cell lung cancer. (English)

1 reference

27 March 2018

author

Juliana Guarize

4

1 reference

27 March 2018

Francesco Petrella

7

1 reference

27 March 2018

Lorenzo Spaggiari

8

object named as

Lorenzo Spaggiari

1 reference

27 March 2018

9

Rafael Rosell

1 reference

27 March 2018

1

Cesare Gridelli

1 reference

27 March 2018

author name string

Antonio Rossi

2

1 reference

27 March 2018

David P Carbone

3

1 reference

27 March 2018

Niki Karachaliou

5

1 reference

27 March 2018

Tony Mok

6

1 reference

27 March 2018

publication date

21 May 2015

1 reference

27 March 2018

Nature Reviews Disease Primers

published in

1 reference

27 March 2018

volume

1

1 reference

27 March 2018

page(s)

15009

1 reference

27 March 2018

https://scigraph.springernature.com/pub.10.1038/nrdp.2015.9

exact match

0 references

cites work

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung ca

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

New pathologic classification of lung cancer: relevance for clinical practice and clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

The IASLC Lung Cancer Staging Project: data elements for the prospective project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

21 January 2018

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Worldwide trends in lung cancer pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Changing trends in the distribution of the histologic types of lung cancer: a review of 4,439 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Lung cancer in never smokers: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Reproducibility of histopathological diagnosis in poorly differentiated NSCLC: an international multiobserver study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

ALK in lung cancer: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Comprehensive molecular profiling of lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Comprehensive genomic characterization of squamous cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Germline EGFR T790M mutation found in multiple members of a familial cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Spatial and temporal diversity in genomic instability processes defines lung cancer evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Interactions between cancer stem cells and their niche govern metastatic colonization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Tumor angiogenesis: molecular pathways and therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

21 January 2018

Fibroblasts in cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

'Cancer associated fibroblasts'--more than meets the eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Pten in stromal fibroblasts suppresses mammary epithelial tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Structural and functional analysis of beta2 microglobulin abnormalities in human lung and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Immunologic and clinical effects of targeting PD-1 in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Lung cancer in never smokers--a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Air pollution and lung cancer incidence in 17 European cohorts: prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Systematic review of the relationship between family history and lung cancer risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Increased risk of lung cancer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Initial Evaluation of the Patient With Lung Cancer: Symptoms, Signs, Laboratory Tests, and Paraneoplastic Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

The noninvasive staging of non-small cell lung cancer: the guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Non-small cell lung cancer: dual-modality PET/CT in preoperative staging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Sputum examination for early detection of lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Molecular sputum analysis for the diagnosis of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Initial diagnosis of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Performance characteristics of different modalities for diagnosis of suspected lung cancer: summary of published evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Effectiveness and safety of endobronchial ultrasound-transbronchial needle aspiration: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

How I do it--optimal methodology for multidirectional analysis of endobronchial ultrasound-guided transbronchial needle aspiration samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Endobronchial ultrasonography using a guide sheath increases the ability to diagnose peripheral pulmonary lesions endoscopically.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Endobronchial ultrasound-guided transbronchial needle aspiration for non-small cell lung cancer staging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Reduced lung-cancer mortality with low-dose computed tomographic screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Lung cancer screening with low-dose helical CT: results from the National Lung Screening Trial (NLST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Overdiagnosis in low-dose computed tomography screening for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Smoking and lung cancer survival: the role of comorbidity and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Lung cancer deaths from indoor radon and the cost effectiveness and potential of policies to reduce them

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Safety and efficacy of video-assisted versus conventional lung resection for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

The quest to overcome resistance to EGFR-targeted therapies in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

First-line crizotinib versus chemotherapy in ALK-positive lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Ceritinib in ALK-rearranged non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Effect of chemotherapy on quality of life in patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

EQ-5D: a measure of health status from the EuroQol Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Early palliative care for patients with metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Oncogenic RIT1 mutations in lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Mutations in UVSSA cause UV-sensitive syndrome and destabilize ERCC6 in transcription-coupled DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Third-generation EGFR-TKIs—a new hope for NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Noncovalent wild-type-sparing inhibitors of EGFR T790M

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Ibrutinib treatment of CLL: the cancer fights back

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

SYK is a critical regulator of FLT3 in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Proteomic and genetic approaches identify Syk as an AML target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Gefitinib induces myeloid differentiation of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Expression of variant isoforms of the tyrosine kinase SYK determines the prognosis of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

TPCA-1 is a direct dual inhibitor of STAT3 and NF-κB and regresses mutant EGFR-associated human non-small cell lung cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Genetics and biomarkers in personalisation of lung cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Genetic insight and therapeutic targets in squamous-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Emerging drugs targeting PD-1 and PD-L1: reality or hope?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Lung cancer screening with low-dose CT (LDCT), or when a public health intervention is beyond the patient’s benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Epidemiology: The dominant malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Precursors to pulmonary neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

An era of lung cancer iconoclasts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Cancer. Attack of the clones

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Prognostic value of smoking status in operated non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Curcumin and resveratrol in combination modulate drug-metabolizing enzymes as well as antioxidant indices during lung carcinogenesis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Need for a New Trial to Evaluate Adjuvant Postoperative Radiotherapy in Non–Small-Cell Lung Cancer Patients With N2 Mediastinal Involvement

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Epidermal growth factor (EGF) activates nuclear factor-kappaB through IkappaBalpha kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of IkappaBalpha

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

Case 16-2013: A girl with irritability, hypersomnia, and somatic symptoms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.9

31 March 2020

Identifiers

DOI

10.1038/NRDP.2015.9

1 reference

27 March 2018

PubMed ID

27188576

1 reference

27 March 2018